This is a paid press release. Contact the press release distributor directly with any inquiries.

Syndax Announces Participation in March Investor Conferences

Syndax Pharmaceuticals, Inc.

Mon, February 23, 2026 at 9:00 PM GMT+9 1 min read

In this article:

SNDX

-4.56%

Syndax Pharmaceuticals, Inc.

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) – Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

**TD Cowen 46th Annual Health Care Conference **in Boston, MA, with a fireside chat on Monday, March 2, 2026, at 1:50 p.m. ET.

**Leerink Global Healthcare Conference **in Miami Beach, FL, with a fireside chat on Wednesday, March 11, 2026, at 1:40 p.m. ET.

**Barclays 28th Annual Global Healthcare Conference** in Miami Beach, FL, with a fireside chat on Thursday, March 12, 2026, at 11:00 a.m. ET.  

A live webcast of the fireside chats will be available in the Investor section of the Company’s website at www.syndax.com, where a replay will also be available for a limited time.

**About Syndax

**Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

Terms and Privacy Policy

Privacy Dashboard

More Info